Healthcare Jun 23, 2022 10:36 AM (GMT+8) · EqualOcean
On June 22, Merck KGaA of Germany announced that its new anti-tumor drug cetuximab injection (trade name: ibital) was approved by China National Drug Administration (nmpa) for the treatment of locally advanced head and neck squamous cell carcinoma (LA SCCHN) in combination with radiotherapy. According to the press release, cetuximab is the first IgG1 monoclonal antibody targeting epidermal growth factor receptor (EGFR) in the world. This is a new breakthrough in the field of head and neck squamous cell carcinoma after the first-line treatment of recurrent and / or metastatic head and neck squamous cell carcinoma, and also the fourth indication approved in China.